TBPH Theravance Biopharma Inc.

26.41
-0.68  -3%
Previous Close 27.09
Open 26.8
Price To Book -110.04
Market Cap 1463411482
Shares 55,411,264
Volume 285,440
Short Ratio
Av. Daily Volume 250,838

SEC filingsSee all SEC filings

  1. 8-K - Current report 181212911
  2. 8-K - Current report 181189856
  3. 8-K - Current report 181173207
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167964
  5. 8-K - Current report 181163177

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released September 20, 2017 - primary endpoint met.
Closed Triple - IMPACT
COPD
Approved June 21, 2013.
VIBATIV (telavancin hydrochloride) for injection
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
Approved April 30, 2015.
BREO ELLIPTA
Asthma
Phase 3 dosing to commence late-2018 or early-2019.
TD-9855
nOH
Phase 3 completion early 2019.
Closed Triple
Asthma
Approval announced September 19, 2017.
Closed Triple
COPD
FDA Approval announced November 9, 2018.
Revefenacin
COPD
Phase 2b data released August 2, 2017. Primary endpoint not met.
Velusetrag (TD-5108)
Gastroparesis
Phase 2 data released June 2016
TD-6450
Hepatitis C virus (HCV)
Phase 3 trial discontinued following recent interim analysis.
Telavancin
Bacteremia
Phase 3 first patient enrolled late February 2015. Data due 2017
Telavancin
Staphylococcus aureus bacteremia
Phase 3 data due in 2016
TD-4208
Chronic obstructive pulmonary disease (COPD
Phase 2 commencement of dosing announced November 21, 2018.
TD-1473
Crohn's Disease
Phase 2b/3 dosing to commence late-2018 or early-2019.
TD-1473
Ulcerative Colitis
Phase 1 dosing announced November 27, 2018.
TD-8236
Asthma

Latest News

  1. See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
  2. Theravance Biopharma to Highlight Innovative Early Research and Clinical Development at R&D Day on December 12 in New York
  3. Theravance Biopharma Announces Closing of Private Placement of $250 Million of 9% Non-Recourse Notes
  4. Theravance Pipeline Strong, Plans Yupelri Launch by Year End
  5. Theravance's Respiratory Disease JAK Inhibitor Enters Phase I
  6. Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor
  7. Theravance JAK Inhibitor Enters Phase II for Crohn's Disease
  8. IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses
  9. Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease
  10. Theravance Biopharma to Present at Two Upcoming Investor Conferences
  11. New Research Coverage Highlights Nexa Resources S.A, Qumu, Clearway Energy, Vermillion, Cantel Medical, and Theravance Biopharma — Consolidated Revenues, Company Growth, and Expectations for 2018
  12. Health Care Digest: A big Berkeley bio incubator, Apple's clinical trial help and more
  13. Theravance Biopharma Highlights Expanded COPD Indication for Trelegy Ellipta in Europe
  14. Edited Transcript of TBPH earnings conference call or presentation 6-Nov-18 10:00pm GMT
  15. Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI™ (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease
  16. Mylan and Theravance Biopharma's COPD treatment gets FDA approval

SEC Filings

  1. 8-K - Current report 181212911
  2. 8-K - Current report 181189856
  3. 8-K - Current report 181173207
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167964
  5. 8-K - Current report 181163177
  6. 8-K - Current report 181161637
  7. UPLOAD [Cover] - SEC-generated letter
  8. 8-K - Current report 181106945
  9. CORRESP [Cover] - Correspondence
  10. 8-K - Current report 18986775